A. J. Ferreri, F. Ciceri, A. A. Brandes, M. Montanari, M. Balzarotti et al., MATILDE chemotherapy regimen for primary CNS lymphoma: Results at a median follow-up of 12 years, Neurology, vol.82, issue.15, pp.1370-1373, 2014.
DOI : 10.1212/WNL.0000000000000314

J. L. Rubenstein, E. D. His, J. L. Johnson, S. H. Jung, M. O. Nakashima et al., Intensive Chemotherapy and Immunotherapy in Patients With Newly Diagnosed Primary CNS Lymphoma: CALGB 50202 (Alliance 50202), Journal of Clinical Oncology, vol.31, issue.25, pp.3061-3068, 2013.
DOI : 10.1200/JCO.2012.46.9957

J. L. Rubenstein, D. Combs, J. Rosenberg, A. Levy, M. Mcdermott et al., Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment, Blood, vol.101, issue.2, pp.466-468, 2003.
DOI : 10.1182/blood-2002-06-1636

T. T. Batchelor, S. A. Grossman, T. Mikkelsen, X. Ye, S. Desideri et al., Rituximab monotherapy for patients with recurrent primary CNS lymphoma, Neurology, vol.76, issue.10, pp.929-930, 2011.
DOI : 10.1212/WNL.0b013e31820f2d94

K. Hoang-huan, E. Bessell, J. Bromberg, A. F. Hottinger, M. Preusser et al., Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology, The Lancet Oncology, vol.16, issue.7, pp.322-332, 2015.
DOI : 10.1016/S1470-2045(15)00076-5

J. L. Rubenstein, J. Fridlyand, L. Abrey, A. Shen, J. Karch et al., Phase I Study of Intraventricular Administration of Rituximab in Patients With Recurrent CNS and Intraocular Lymphoma, Journal of Clinical Oncology, vol.25, issue.11, pp.1350-1356, 2007.
DOI : 10.1200/JCO.2006.09.7311

J. L. Rubenstein, J. Li, L. Chen, R. Advani, J. Drappatz et al., Multicenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphoma, Blood, vol.121, issue.5, pp.745-751, 2013.
DOI : 10.1182/blood-2012-07-440974

C. Kadoch, J. Li, V. S. Wong, L. Chen, S. Cha et al., Complement Activation and Intraventricular Rituximab Distribution in Recurrent Central Nervous System Lymphoma, Clinical Cancer Research, vol.20, issue.4, pp.1029-1041, 2013.
DOI : 10.1158/1078-0432.CCR-13-0474

C. Soussain, K. Hoang-xuan, L. Taillandier, E. Fourme, S. Choquet et al., Intensive Chemotherapy Followed by Hematopoietic Stem-Cell Rescue for Refractory and Recurrent Primary CNS and Intraocular Lymphoma: Soci??t?? Fran??aise de Greffe de Mo??lle Osseuse-Th??rapie Cellulaire, Journal of Clinical Oncology, vol.26, issue.15, pp.2512-2518, 2008.
DOI : 10.1200/JCO.2007.13.5533

G. Illerhaus, F. Muller, F. Feurhake, A. O. Schafer, C. Ostertag et al., High-dose chemotherapy and autologous stem-cell transplantation without consolidating 62-Montesinos-Rongen Gene expression profiling suggests primary central nervous system lymphomas to be derived from a late germinal center B cell, Leukemia, vol.22, pp.400-405, 2008.

O. Levy, L. M. Deangelis, D. A. Filippa, K. S. Panageas, and L. E. Abrey, Bcl-6 predicts improved prognosis in primary central nervous system lymphoma, Cancer, vol.24, issue.1, pp.151-156, 2008.
DOI : 10.1002/cncr.23149

K. M. Braaten, R. A. Betensky, L. De-leval, Y. Okada, F. H. Hochberg et al., BCL-6 expression predicts improved survival in patients with primary central nervous system lymphoma, Clin Cancer Res, vol.9, pp.1063-1069, 2003.

R. D. Gascoyne, S. A. Adomat, S. Krajewski, M. Krajewska, D. E. Horsman et al., Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma, Blood, vol.90, pp.244-251, 1997.

A. Brunn, I. Nagel, M. Montesinos-rongen, W. Klapper, I. Vater et al., Frequent triple-hit expression of MYC, BCL2, and BCL6 in primary lymphoma of the central nervous system and absence of a favorable MYClowBCL2low subgroup may underlie the inferior prognosis as compared to systemic diffuse large B cell lymphomas, Acta Neuropathologica, vol.346, issue.4, pp.603-605, 2013.
DOI : 10.1007/s00401-013-1169-7

M. Nozaki, M. Tada, R. Matsumoto, Y. Sawamura, H. Abe et al., Rare occurrence of inactivating p53 gene mutations in primary non-astrocytic tumors of the central nervous system: reappraisal by yeast functional assay, Acta Neuropathologica, vol.95, issue.3, pp.291-296, 1998.
DOI : 10.1007/s004010050800

C. Steidl, T. Lee, S. P. Shah, P. Farinha, G. Han et al., Tumor-Associated Macrophages and Survival in Classic Hodgkin's Lymphoma, New England Journal of Medicine, vol.362, issue.10, pp.875-885, 2010.
DOI : 10.1056/NEJMoa0905680

S. J. Nam, H. Go, J. H. Paik, T. M. Kim, D. S. Heo et al., An increase of M2 macrophages predicts poor prognosis in patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone, Leukemia & Lymphoma, vol.55, issue.11
DOI : 10.4049/jimmunol.0713732

S. Riihijärvi, I. Fiskvik, M. Taskinen, H. Vajavaara, M. Tikkala et al., Prognostic influence of macrophages in patients with diffuse large B-cell lymphoma: a correlative study from a Nordic phase II trial, Haematologica, vol.100, issue.2, pp.238-245, 2015.
DOI : 10.3324/haematol.2014.113472

S. M. Ansell, M. Stenson, T. M. Habermann, D. F. Jelinek, and T. Witzig, CD4+ T-Cell Immune Response to Large B-Cell Non-Hodgkin???s Lymphoma Predicts Patient Outcome, Journal of Clinical Oncology, vol.19, issue.3
DOI : 10.1200/JCO.2001.19.3.720

M. Ponzoni, F. Berger, C. Chassagne-clement, M. Tinguely, A. Jouvet et al., Reactive perivascular T-cell infiltrate predicts survival in primary central nervous system B-cell lymphomas, British Journal of Haematology, vol.5, issue.3, pp.316-323, 2007.
DOI : 10.1038/nrc1586

S. Donnou, C. Galand, C. Daussy, L. Crozet, W. H. Fridman et al., Immune adaptive microenvironment profiles in intracerebral and intrasplenic lymphomas share common characteristics, Clinical & Experimental Immunology, vol.453, issue.3, pp.329-337, 2011.
DOI : 10.1111/j.1365-2249.2011.04416.x

S. M. Ansell, A. M. Lesokhin, I. Borrello, A. Halwani, E. C. Scott et al., PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma, New England Journal of Medicine, vol.372, issue.4, pp.311-319, 2015.
DOI : 10.1056/NEJMoa1411087

J. R. Westin, F. Chu, M. Zhang, L. E. Fayad, L. W. Kwak et al., Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial, The Lancet Oncology, vol.15, issue.1, pp.69-77, 2014.
DOI : 10.1016/S1470-2045(13)70551-5

A. S. Berghoff, G. Ricken, G. Widhalm, O. Rajky, J. A. Hainfellner et al., PD1 (CD279) and PD-L1 (CD274, B7H1) expression in primary central nervous system lymphomas (PCNSL), PD1 (CD279) and PD-L1 (CD274,B7H1) expression in primary central nervous system lymphomas (PCNSL), pp.42-49, 2014.
DOI : 10.5414/NP300698

A. H. Banham, J. M. Connors, P. J. Brown, J. L. Cordell, G. Ott et al., Expression of the FoxP1 transcription factor is strongly associated with inferior survival in patients with diffuse large B-cell lymphoma, Clin Cancer Res, vol.11, pp.1065-1072, 2005.